Literature DB >> 21536923

FDA cGMP requirements for PET drugs.

Jeffrey P Norenberg, Sally Schwarz, Henry VanBrocklin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21536923

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  3 in total

Review 1.  PET/SPECT imaging agents for neurodegenerative diseases.

Authors:  Lin Zhu; Karl Ploessl; Hank F Kung
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

Review 2.  The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1.

Authors:  Hsiaoju S Lee; Sally W Schwarz; Erin K Schubert; Delphine L Chen; Robert K Doot; Mehran Makvandi; Lilie L Lin; Elizabeth S McDonald; David A Mankoff; Robert H Mach
Journal:  Radiol Imaging Cancer       Date:  2022-01

3.  Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In-XYIMSR-01 for phase I regulatory approval.

Authors:  Ravindra A De Silva; Michael A Gorin; Ronnie C Mease; Il Minn; Ala Lisok; Donika Plyku; Sridhar Nimmagadda; Mohamad E Allaf; Xing Yang; George Sgouros; Steven P Rowe; Martin G Pomper
Journal:  J Labelled Comp Radiopharm       Date:  2021-03-04       Impact factor: 1.921
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.